New York University (NYU) Langone Medical Center announced the appointment of physician-scientist and brain tumor specialist Andrew S. Chi, MD, PhD, as Chief of Neuro-Oncology for its Laura and Isaac Perlmutter Cancer Center and Co-Director of the NYU Langone Brain Tumor Center.
In his new role, Dr. Chi will lead all neuro-oncology-related programs. In addition, he will co-lead the NYU Langone Brain Tumor Center in partnership with John G. Golfinos, MD, Chair of the Department of Neurosurgery.
Clinical and Investigative Expertise
Dr. Chi comes to NYU from Massachusetts General Hospital, Dana-Faber/Harvard Cancer Center, and Harvard Medical School, where he held the title of Assistant Professor of Neurology. His clinical work at Massachuetts General Hospital included the neuro-oncologic treatment of primary brain tumors, metastatic tumors to the central nervous system, and neurologic complications of cancer.
In addition to his clinical expertise, Dr. Chi’s investigative work principally focuses on the identification of molecular genetic alterations that underlie the development, progression, and treatment resistance of brain tumors. By understanding the mechanism by which tumor genome alterations drive the growth of cancers, therapeutic strategies can be designed to improve outcomes for patients.
After completing his postdoctoral research at Massachusetts General Hospital, Dr. Chi began his research studies of the underlying genetic mechanisms of brain tumors in the laboratory on a team with Daniel P. Cahill, MD, PhD, and A. John Iafrate, MD, PhD, where they advanced the understanding of the molecular genetics of gliomas and uncovered novel molecular targets for the treatments for brain tumors.
Dr. Chi earned his medical degree and doctorate in biochemistry and molecular biology from Chicago Medical School. He completed his residency in neurology at Harvard Medical School, based at Massachusetts General Hospital and Brigham and Women’s Hospital, serving his final year as Chief Resident.
“I am thrilled to join NYU Langone and to work with the respected faculty at the Perlmutter Cancer Center,” said Dr. Chi. “We share a similar vision of innovation for the Cancer Center, and I am confident that as a result of these efforts, we will see major scientific and clinical advances against these horrible diseases in the coming years.” ■
